Skip to content

Correlation of VEGF-A and Fluid Balance in Septic Shock

Correlation of VEGF-A and Fluid Balance in Septic Shock

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04474431
Acronym
VEGFluid
Enrollment
103
Registered
2020-07-16
Start date
2019-12-24
Completion date
2023-10-17
Last updated
2026-02-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Septic Shock

Brief summary

VEGF is a key molecule in the control of vascular permeability via interactions with the VEGF-receptor on the endothelial cell. Several authors reported plasma VEGF levels are elevated in sepsis shock and associated with increased mortality (1,2). In septic shock, the main elements of treatment are intravenous fluids, appropriate antibiotics and vasopressors. Some authors observed positive fluid balance is associated with increased mortality rates in patients (3,4). To the best of our knowledge, no studies have shown a correlation between VEGF levels and the fluid balance. The aim of our study was to determine the role of VEGF in capillary leakage and the positive fluid balance in septic shock.

Interventions

OTHEREvaluation of VEGF-A levels in patients with septic shock is positively correlated with a positive fluid balance.

Evaluation of VEGF-A levels in patients with septic shock is positively correlated with a positive fluid balance.

Sponsors

University Hospital, Rouen
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patient above 18 years old * Patient with septic shock (presence of an infection, hypotension with mean arterial pressure less than 65mmHg and the need for vasopressor treatment (minimum dose 0,3µ/kg/min) * Person informed and signed consent.

Exclusion criteria

* Death predicted within 24 hours * Limitation of therapeutic attitudes * Treatment with bevacizumab in the past 6 months * Pathologies with endothelial dysfunction (scleroderma, clarkson syndrome...) * Acute renal failure (KDIGO 3) at ICU admission defined by : * Increase in serum creatinine to \> 354µmol/l or 3 times baseline OR * Urine output ≤0,3 ml/kg/h for 24h OR * Anuria for 12h * Morbid obesity with a body mass index (BMI) \> 35 kg/m². * Limb amputation * Morbid obesity with a body mass index (BMI) \> 35 kg/m². * Amputation of a limb * Pregnant or nursing women * Inability to obtain consent from family * Person with guardianship or curatorship

Design outcomes

Primary

MeasureTime frameDescription
Show that elevation of VEGF-A levels at D1 in the management of patients with septic shock is positively correlated with a positive fluid balance.1 dayPlasma assay of the VEGF-A by enzyme-linked immunosorbent assay (ELISA) and calculated fluid balance at D1 of ICU admission.

Secondary

MeasureTime frameDescription
Correlation of VEGF-A levels and fluid balance at D3 of ICU admission.3 daysPlasma assay of the VEGF-A by enzyme-linked immunosorbent assay (ELISA) and calculated fluid balance at D3 of ICU admission.
Correlation of VEGF-A levels with edema at D1 and D3 of ICU admission.1 and 3 daysPlasma determination of endothelial dysfunction biomarkers by the enzyme-linked immunosorbent assay (ELISA) method: VEGF-A at D1 and D3 of ICU admission edema evaluation at D1 and D3 of ICU admission by: * Weight * fluid balance: difference between input (fluid therapy) and output (urine output) * Ultrasound-measured thickness of subcutaneous tissue * Measurement of total, intra and extra cellular body water evaluated by bioimpedancemetry
Correlation of Soluble Vascular Endothelial Growth Factor Receptor 1 (sFlt1) levels and edema at D1 and D3 of ICU admission.1 and 3 daysPlasma determination of endothelial dysfunction biomarkers by the enzyme-linked immunosorbent assay (ELISA) method: sFlt1 at D1 and D3 of ICU admission edema evaluation at D1 and D3 of ICU admission by: * Weight * fluid balance: difference between input (fluid therapy) and output (urine output) * Ultrasound-measured thickness of subcutaneous tissue * Measurement of total, intra and extra cellular body water evaluated by bioimpedancemetry
Correlation of sFlt1 levels and fluid balance at D1 and D3 of ICU admission.1 and 3 daysPlasma determination of endothelial dysfunction biomarkers by the enzyme-linked immunosorbent assay (ELISA) method: sFlt1 \- fluid balance: difference between input (fluid therapy) and output (urine output)
Correlation of VEGF A levels and microcirculation at D1 and D3 of ICU1 and 3 daysPlasma determination of endothelial dysfunction biomarkers by the enzyme-linked immunosorbent assay (ELISA) method: VEGF-A Study of microcirculation in vivo by Glycocheck: capillary density, Blood flow and red cell velocity, Endothelial glycocalyx function at D1 and D3 of ICU admission
Evolution of VEGF A and sFLT1 levels between D1 and D3 of ICU admission.1 and 3 daysPlasma determination of endothelial dysfunction biomarkers by the enzyme-linked immunosorbent assay (ELISA) method: VEGF-A and sFlt1 at D1 and D3 of their management in intensive care units.
Correlation of VEGF A levels at D1 and mortality at D28 of management.28 daysSurvival at D28 of ICU admission

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 7, 2026